|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUAK1 |
Gene summary for NUAK1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUAK1 | Gene ID | 9891 |
| Gene name | NUAK family kinase 1 | |
| Gene Alias | ARK5 | |
| Cytomap | 12q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024RBL3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9891 | NUAK1 | P2T-E | Human | Esophagus | ESCC | 3.16e-50 | 1.23e+00 | 0.1177 |
| 9891 | NUAK1 | P8T-E | Human | Esophagus | ESCC | 4.10e-18 | 5.29e-01 | 0.0889 |
| 9891 | NUAK1 | P10T-E | Human | Esophagus | ESCC | 4.33e-27 | 4.76e-01 | 0.116 |
| 9891 | NUAK1 | P11T-E | Human | Esophagus | ESCC | 8.05e-05 | 4.66e-01 | 0.1426 |
| 9891 | NUAK1 | P12T-E | Human | Esophagus | ESCC | 2.79e-09 | 2.27e-01 | 0.1122 |
| 9891 | NUAK1 | P15T-E | Human | Esophagus | ESCC | 7.27e-08 | 2.54e-01 | 0.1149 |
| 9891 | NUAK1 | P16T-E | Human | Esophagus | ESCC | 1.04e-11 | 2.72e-01 | 0.1153 |
| 9891 | NUAK1 | P21T-E | Human | Esophagus | ESCC | 1.74e-20 | 5.97e-01 | 0.1617 |
| 9891 | NUAK1 | P22T-E | Human | Esophagus | ESCC | 6.00e-12 | 2.36e-01 | 0.1236 |
| 9891 | NUAK1 | P26T-E | Human | Esophagus | ESCC | 4.84e-24 | 5.03e-01 | 0.1276 |
| 9891 | NUAK1 | P27T-E | Human | Esophagus | ESCC | 6.91e-07 | 2.36e-01 | 0.1055 |
| 9891 | NUAK1 | P31T-E | Human | Esophagus | ESCC | 6.90e-16 | 3.14e-01 | 0.1251 |
| 9891 | NUAK1 | P32T-E | Human | Esophagus | ESCC | 1.44e-11 | 2.86e-01 | 0.1666 |
| 9891 | NUAK1 | P36T-E | Human | Esophagus | ESCC | 2.95e-10 | 4.72e-01 | 0.1187 |
| 9891 | NUAK1 | P37T-E | Human | Esophagus | ESCC | 1.71e-07 | 3.53e-01 | 0.1371 |
| 9891 | NUAK1 | P40T-E | Human | Esophagus | ESCC | 9.86e-08 | 2.74e-01 | 0.109 |
| 9891 | NUAK1 | P42T-E | Human | Esophagus | ESCC | 5.63e-13 | 4.73e-01 | 0.1175 |
| 9891 | NUAK1 | P44T-E | Human | Esophagus | ESCC | 1.60e-02 | 2.40e-01 | 0.1096 |
| 9891 | NUAK1 | P47T-E | Human | Esophagus | ESCC | 1.20e-02 | 1.54e-01 | 0.1067 |
| 9891 | NUAK1 | P48T-E | Human | Esophagus | ESCC | 1.53e-08 | 2.69e-01 | 0.0959 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
| GO:0072331111 | Esophagus | ESCC | signal transduction by p53 class mediator | 121/8552 | 163/18723 | 9.61e-14 | 4.69e-12 | 121 |
| GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
| GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
| GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
| GO:0009267110 | Esophagus | ESCC | cellular response to starvation | 110/8552 | 156/18723 | 2.63e-10 | 7.37e-09 | 110 |
| GO:004259419 | Esophagus | ESCC | response to starvation | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
| GO:1901796111 | Esophagus | ESCC | regulation of signal transduction by p53 class mediator | 70/8552 | 93/18723 | 5.69e-09 | 1.18e-07 | 70 |
| GO:0035304111 | Esophagus | ESCC | regulation of protein dephosphorylation | 66/8552 | 90/18723 | 8.82e-08 | 1.48e-06 | 66 |
| GO:0035303111 | Esophagus | ESCC | regulation of dephosphorylation | 88/8552 | 128/18723 | 1.04e-07 | 1.71e-06 | 88 |
| GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00421492 | Esophagus | ESCC | cellular response to glucose starvation | 36/8552 | 48/18723 | 3.43e-05 | 2.80e-04 | 36 |
| GO:00075699 | Esophagus | ESCC | cell aging | 81/8552 | 132/18723 | 2.00e-04 | 1.27e-03 | 81 |
| GO:0043666110 | Esophagus | ESCC | regulation of phosphoprotein phosphatase activity | 40/8552 | 58/18723 | 2.83e-04 | 1.71e-03 | 40 |
| GO:001092115 | Esophagus | ESCC | regulation of phosphatase activity | 52/8552 | 84/18723 | 1.98e-03 | 8.90e-03 | 52 |
| GO:00903984 | Esophagus | ESCC | cellular senescence | 54/8552 | 93/18723 | 1.08e-02 | 3.67e-02 | 54 |
| GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
| GO:007149622 | Liver | HCC | cellular response to external stimulus | 191/7958 | 320/18723 | 3.40e-10 | 1.13e-08 | 191 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| NUAK1 | TUF | Colorectum | AD | POMP,BRINP1,EDIL3, etc. | 6.48e-03 |  |
| NUAK1 | EE | Colorectum | AD | POMP,BRINP1,EDIL3, etc. | 3.61e-02 | |
| NUAK1 | CT | Colorectum | AD | POMP,BRINP1,EDIL3, etc. | 3.41e-03 | |
| NUAK1 | SSC | Colorectum | AD | POMP,BRINP1,EDIL3, etc. | 6.66e-03 | |
| NUAK1 | STM | Colorectum | MSI-H | POMP,BRINP1,EDIL3, etc. | 1.61e-02 |  |
| NUAK1 | CT | Colorectum | MSI-H | POMP,BRINP1,EDIL3, etc. | 2.22e-16 | |
| NUAK1 | TUF | Colorectum | MSS | POMP,BRINP1,EDIL3, etc. | 2.33e-02 |  |
| NUAK1 | CT | Colorectum | MSS | POMP,BRINP1,EDIL3, etc. | 0.00e+00 | |
| NUAK1 | EE | Colorectum | SER | POMP,BRINP1,EDIL3, etc. | 5.76e-02 |  |
| NUAK1 | SSC | Colorectum | SER | POMP,BRINP1,EDIL3, etc. | 1.09e-03 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUAK1 | SNV | Missense_Mutation | c.736N>G | p.Leu246Val | p.L246V | O60285 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NUAK1 | SNV | Missense_Mutation | novel | c.1404N>T | p.Leu468Phe | p.L468F | O60285 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NUAK1 | SNV | Missense_Mutation | c.623N>G | p.Phe208Cys | p.F208C | O60285 | protein_coding | deleterious(0.03) | benign(0.049) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD | |
| NUAK1 | SNV | Missense_Mutation | c.949N>A | p.Cys317Ser | p.C317S | O60285 | protein_coding | tolerated(0.46) | possibly_damaging(0.521) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| NUAK1 | SNV | Missense_Mutation | c.1515N>G | p.Ser505Arg | p.S505R | O60285 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NUAK1 | SNV | Missense_Mutation | rs757219955 | c.1382C>T | p.Thr461Met | p.T461M | O60285 | protein_coding | tolerated(0.11) | benign(0.02) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| NUAK1 | SNV | Missense_Mutation | rs759029750 | c.1699C>T | p.Arg567Cys | p.R567C | O60285 | protein_coding | deleterious(0.01) | probably_damaging(0.959) | TCGA-D8-A73X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| NUAK1 | SNV | Missense_Mutation | c.1327N>T | p.Pro443Ser | p.P443S | O60285 | protein_coding | tolerated(0.74) | benign(0) | TCGA-E2-A15H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | herceptin | SD | |
| NUAK1 | SNV | Missense_Mutation | rs779923959 | c.445N>A | p.Arg149Ser | p.R149S | O60285 | protein_coding | tolerated(0.13) | possibly_damaging(0.498) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| NUAK1 | SNV | Missense_Mutation | novel | c.260N>C | p.Arg87Pro | p.R87P | O60285 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9891 | NUAK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 310264738 | CERDULATINIB | |
| 9891 | NUAK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 315661259 | ||
| 9891 | NUAK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 310264757 | ||
| 9891 | NUAK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565727 | ||
| 9891 | NUAK1 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565819 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |